1. Market Research
  2. > All Companies
  3. > Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eli Lilly and Company (Lilly) is a US based innovation driven pharmaceutical company. It carries out the discovery, development, manufacture and marketing of products. The company’s product portfolio consists of neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceutical products. The company’s research efforts are mainly focused on five therapeutic domains, namely, cancer; endocrine diseases such as diabetes, obesity, and musculoskeletal disorders; central nervous system; autoimmune diseases; and cardiovascular diseases. The company’s products are sold in several countries across the world. Lilly is headquartered in Indiana, the US.

The company focuses on creating value for all its stakeholders by enhancing the flow of innovative new medicines in human health and animal health providing improved outcomes for individual patients across the world. To this end, the company in March 2015 entered into a major collaboration agreement with Innovent Biologics, Inc. to support the development and potential commercialization of at least three cancer treatments over the next decade.

Eli Lilly and Company Key Recent Developments

Mar 20, 2015: Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
Feb 11, 2015: Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College
Feb 04, 2015: The Lilly Foundation Commits $1 Million To Support AMPATH Oncology Institute In Kenya
Jan 30, 2015: Lilly Reports Fourth-Quarter And Full-Year 2014 Results, Updates 2015 Guidance
Jan 07, 2015: Lilly Provides Update On Strategy And Announces 2015 Financial Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Eli Lilly and Company (LLY) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Eli Lilly and Company - Key Facts 6
Eli Lilly and Company - Key Employees 7
Eli Lilly and Company - Key Employee Biographies 9
Eli Lilly and Company - Major Products and Services 10
Eli Lilly and Company - Pharmaceutical Pipeline Products Data 12
Eli Lilly and Company, Pipeline Products by Therapy Area 12
Eli Lilly and Company, Pipeline Products by Development Phase 13
Eli Lilly and Company - History 23
Eli Lilly and Company - Company Statement 35
Eli Lilly and Company - Locations And Subsidiaries 38
Head Office 38
Other Locations and Subsidiaries 38
Eli Lilly and Company - Key Manufacturing Facilities 46
Joint Venture 46
Section 2 - Company Analysis 47
Eli Lilly and Company - Business Description 47
Business Description - Animal Health Products 47
Animal Health Products - Overview 47
Animal Health Products - Financials 47
Animal Health Products - Key Strategies 47
Business Description - Human Pharmaceutical Products 48
Human Pharmaceutical Products - Overview 48
Human Pharmaceutical Products - Financials 48
Human Pharmaceutical Products - Key Strategies 48
Eli Lilly and Company - Corporate Strategy 49
Eli Lilly and Company - SWOT Analysis 50
SWOT Analysis - Overview 50
Eli Lilly and Company - Strengths 50
Strength - Emphasis on Research 50
Strength - Strong Portfolio of Endocrinology Products 50
Strength - Strategic Collaborations 50
Eli Lilly and Company - Weaknesses 51
Weakness - Decline in Revenue in the US 51
Weakness - Cost Control 51
Weakness - Loss of Exclusivity: Cymbalta 51
Eli Lilly and Company - Opportunities 52
Opportunity - New Product Approvals and Launches 52
Opportunity - Product Pipeline 52
Opportunity - Expansion of Animal Health Business 52
Eli Lilly and Company - Threats 53
Threat - Influx of Generics 53
Threat - Product Litigations 53
Threat - Competitive Pressures 53
Eli Lilly and Company - Key Competitors 54
Section 3 - Company Financial Ratios 55
Financial Ratios - Capital Market Ratios 55
Financial Ratios - Annual Ratios 56
Performance Chart 58
Financial Performance 58
Financial Ratios - Interim Ratios 59
Financial Ratios - Ratio Charts 60
Section 4 - Company's Lifesciences Financial Deals and Alliances 61
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 61
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 62
Eli Lilly and Company, Recent Deals Summary 63
Section 5 - Company's Recent Developments 65
Mar 20, 2015: Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World 65
Feb 11, 2015: Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College 66
Feb 04, 2015: The Lilly Foundation Commits $1 Million To Support AMPATH Oncology Institute In Kenya 67
Jan 30, 2015: Lilly Reports Fourth-Quarter And Full-Year 2014 Results, Updates 2015 Guidance 68
Jan 07, 2015: Lilly Provides Update On Strategy And Announces 2015 Financial Guidance 75
Jan 05, 2015: Lilly Announces Promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development 77
Jan 05, 2015: Lilly Announces Promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development 78
Dec 18, 2014: Biothera Participates in Cancer Research UK Combinations Alliance 79
Dec 18, 2014: Biothera Participates in Cancer Research UK Combinations Alliance 80
Dec 15, 2014: Lilly Announces Dividend Increase 81
Section 6 - Appendix 82
Methodology 82
Ratio Definitions 82
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Eli Lilly and Company, Key Facts 6
Eli Lilly and Company, Key Employees 7
Eli Lilly and Company, Key Employee Biographies 9
Eli Lilly and Company, Major Products and Services 10
Eli Lilly and Company, Number of Pipeline Products by Therapy Area 12
Eli Lilly and Company, Number of Pipeline Products by Development Stage 13
Eli Lilly and Company, Pipeline Products By Therapy Area and Development Phase 14
Eli Lilly and Company, History 23
Eli Lilly and Company, Subsidiaries 38
Eli Lilly and Company, Key Manufacturing Facilities 46
Eli Lilly and Company, Joint Venture 46
Eli Lilly and Company, Key Competitors 54
Eli Lilly and Company, Ratios based on current share price 55
Eli Lilly and Company, Annual Ratios 56
Eli Lilly and Company, Interim Ratios 59
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 61
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 62
Eli Lilly and Company, Recent Deals Summary 63
Currency Codes 82
Capital Market Ratios 82
Equity Ratios 83
Profitability Ratios 83
Cost Ratios 84
Liquidity Ratios 84
Leverage Ratios 85
Efficiency Ratios 85

List of Figures
Eli Lilly and Company, Pipeline Products by Therapy Area 12
Eli Lilly and Company, Pipeline Products by Development Phase 13
Eli Lilly and Company, Performance Chart (2010 - 2014) 58
Eli Lilly and Company, Ratio Charts 60
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 61
Eli Lilly and Company, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 62

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 718 303 2384

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.